Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berberine - Xintria Pharmaceutical Corporation

Drug Profile

Berberine - Xintria Pharmaceutical Corporation

Latest Information Update: 11 Jun 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chinese Academy of Medical Sciences
  • Developer Xintria Pharmaceutical Corporation
  • Class Alkaloids; Antidiarrhoeals; Antiprotozoals; Benzylisoquinolines; Berberine alkaloids; Cardiovascular therapies; Herbal medicines; Heterocyclic compounds with 4 or more rings; Small molecules; Traditional Chinese medicine
  • Mechanism of Action Alpha adrenergic receptor antagonists; Cholesterol modulators; Triglyceride modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Cardiovascular disorders

Most Recent Events

  • 01 Jun 2019 Phase-II clinical trials in Cardiovascular disorders in USA (PO) (NCT03976336)
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in USA
  • 25 Mar 2009 Preclinical trials in Cardiovascular disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top